FIRST-LINE NIVOLUMAB PLUS IPILIMUMAB COMBINED WITH TWO CYCLES OF CHEMOTHERAPY IN PATIENTS WITH NON-SMALL-CELL LUNG CANCER

Abstract

The immune checkpoint inhibitors reinstating endogenous antitumor immunity have radically changed the therapy paradigm in advanced non-small-cell lung cancer (NSCLC) over the past years. By combining immune checkpoint inhibitors with other treatment modalities (chemotherapy, other checkpoint inhibitors), observed responses and survival rates increased significantly, regardless of programmed death-ligand 1 (PD-L1) expression. The combination of nivolumab plus ipilimumab with two cycles of chemotherapy is the first dual immunotherapy-based treatment option approved for adult patients with metastatic NSCLC whose tumors have no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation in the European Union.